EVO
Evotec SE
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · DE
$1.86
−2.11%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.8x
Market Cap
$661.02M
MomentumView details →
1D Return
−2.11%
YTD Return
−40.10%
RSI (14)
39.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.8x
Market Cap
$661.02M
RSI (14)
39.5
MomentumView details →
1D Return
−2.11%
YTD Return
−40.10%
SummaryUpdated Jun 1, 2026
Evotec SE (NASDAQ:EVO) is a German drug discovery and development company founded in 1993 and headquartered in Hamburg. Originally incorporated as Evotec AG, the company changed its name to Evotec SE in April 2019 and went public in 2004. Evotec operates as a strategic partner to pharmaceutical and biotechnology companies worldwide, providing integrated drug discovery services and biologics manufacturing capabilities. The company has evolved from a traditional contract research organization into a technology-driven platform that combines advanced scientific capabilities with manufacturing expertise to accelerate drug development across multiple therapeutic areas.
Similar companies
Latest newsMore news →
Evotec SE and Plectonic Biotech announced a research collaboration to explore a novel immunotherapy approach for solid tumors, combining Evotec's BiTco costimulatory CD2 bispecifics platform with Plectonic's LOGIBODY® technology.3d agoEvotec SE announced a strategic R&D collaboration with Odyssey Therapeutics to discover new treatments for autoimmune and inflammatory diseases using Evotec's AI-enabled discovery platform.30d ago